TSPAN8 and metastatic neoplasm: Vice versa, TSPAN8 upregulated in OC and grouped into C3 to C6 (Figure 2C) would be a possible therapeutic target to reduced metastatic disease previously demonstrated in a preclinical setting using TSPAN8‐blocking antibody [35].